Featured Content

Dean Gesme, MD
FACP FACPE FASCO President, Minnesota Oncology

Similar Immunotherapy Trials, Different Results: Early Signals From PD-1 Checkpoint Inhibitors in First-Line NSCLC

(Medscape Oncology) Aug 25, 2016 - Dr. Jack West analyzes the most recent data on PD-1 checkpoint inhibitors as first-line non-small cell lung cancer therapy and predicts how these relatively new agents will affect standard treatments.

Commentary: Patient selection biases and our attempts to compare dissimilar trials makes rapid assessment of these lung cancer...



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Lung Cancer Doctors Eye Merck's Keytruda Over Bristol's Opdivo

(Reuters) Aug 25, 2016 - Recent clinical trial results are likely to lead doctors to treat more patients who have a common form of lung cancer with a Merck drug at the expense of a Bristol-Myers Squibb medication at least until more data emerges, oncologists and analysts say.
read article »

Cancer Researchers: It's Time To Pay More Attention To 'Miracle' Patients

(Washington Post/To Your Health) Aug 26, 2016 - Because they deviate so far from the norm, these "exceptional responders" are often overlooked.
read article (free registration required) »

Hopes Dashed for Rare Bone Cancer Treatment

(Philadelphia Inquirer/HealthDay News) Aug 26, 2016 - Adding extra drugs to chemotherapy doesn't benefit patients with a rare type of bone cancer, according to a new study.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Similar Immunotherapy Trials, Different Results: Early Signals From PD-1 Checkpoint Inhibitors in First-Line NSCLC (Medscape Oncology)

Patient selection biases and our attempts to compare dissimilar trials makes rapid assessment of these lung cancer...posted by: Dean Gesme, MD

A Path Forward on Medicare Payment Reform for Physician-Administered Drugs (Morning Consult)

Well there sure is a lot to digest in this report. I agree that there is much that would need to be changed in...posted by: Thomas Marsland, MD

Cancer Drug Companies Cut Prices to Win NHS Approval (The Guardian [UK])

So it appears that the pharmaceutical industry can adapt pricing. I found it interesting that NICE is able to...posted by: Thomas, Marsland, MD

NICE Recommends Crizotinib, First Pill For Lung Cancer (NICE)

I hesitate to call this a great advance, because it's only bringing the UK up to the level of the clear standard...posted by: H. Jack, West, MD

Study Finds Thyroid Cancer Diagnoses Rise, But Treatment May Not Be Best (NBC News)

Well differentiated thyroid cancer is definitely over treated by US physicians. Patients and the media need reassurance...posted by: Dean, Gesme, MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Navigating Cancer has 1 job posted.


Bayer Pharmaceuticals has 1 job posted.


Touchpoint Solutions has over 20 jobs posted.


Check out the OBR Job Board here.





The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
MTP +18.28%
ARGS +4.74%
IMDZ +4.42%
NYMX -23.72%
XBIT -8.27%
MNKD -5.61%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: September 1, 2016
Company: Blincyto® (blinatumomab)
Product: Amgen Inc.

Date: September 10, 2016
Company: Genmab A/S / Novartis
Product: Arzerra® (ofatumumab)

Date: Q3 2016
Company: OncoGenex Pharmaceuticals
Product: Custirsen

See All OBR Radar items»